GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » YSB Inc (HKSE:09885) » Definitions » ROE %

YSB (HKSE:09885) ROE % : 2.20% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is YSB ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. YSB's annualized net income for the quarter that ended in Jun. 2024 was HK$47 Mil. YSB's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was HK$2,137 Mil. Therefore, YSB's annualized ROE % for the quarter that ended in Jun. 2024 was 2.20%.

The historical rank and industry rank for YSB's ROE % or its related term are showing as below:

HKSE:09885' s ROE % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.72
Current: 0.72

During the past 5 years, YSB's highest ROE % was 0.72%. The lowest was 0.00%. And the median was 0.00%.

HKSE:09885's ROE % is ranked worse than
62.32% of 629 companies
in the Healthcare Providers & Services industry
Industry Median: 4.83 vs HKSE:09885: 0.72

YSB ROE % Historical Data

The historical data trend for YSB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YSB ROE % Chart

YSB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROE %
- - - - 0.70

YSB Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Get a 7-Day Free Trial - - -4.07 2.20 -0.62

Competitive Comparison of YSB's ROE %

For the Pharmaceutical Retailers subindustry, YSB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YSB's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, YSB's ROE % distribution charts can be found below:

* The bar in red indicates where YSB's ROE % falls into.



YSB ROE % Calculation

YSB's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-3507.21/( (-4858.581+2099.795)/ 2 )
=-3507.21/-1379.393
=N/A %

YSB's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=46.98/( (2099.795+2174.45)/ 2 )
=46.98/2137.1225
=2.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


YSB  (HKSE:09885) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=46.98/2137.1225
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(46.98 / 18977.212)*(18977.212 / 5708.319)*(5708.319 / 2137.1225)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.25 %*3.3245*2.671
=ROA %*Equity Multiplier
=0.83 %*2.671
=2.20 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=46.98/2137.1225
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (46.98 / 27.382) * (27.382 / -69.124) * (-69.124 / 18977.212) * (18977.212 / 5708.319) * (5708.319 / 2137.1225)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.7157 * -0.3961 * -0.36 % * 3.3245 * 2.671
=2.20 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


YSB ROE % Related Terms

Thank you for viewing the detailed overview of YSB's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


YSB Business Description

Traded in Other Exchanges
Address
No. 8 Brand Street, No. 397 Xingang Middle Road, Yaoshibang Building, TIT Creative Industry Zone, Guangzhou, CHN
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The Company is committed to using digitalization to empower participants in the out-of-hospital pharmaceutical market, including pharmaceutical companies, distributors, vendors, pharmacies and primary healthcare institutions, and strives to bring pharmaceutical health products and services to the downstream safely and efficiently, so that users can easily obtain a large number of comprehensive and high-quality drugs at a fair and transparent price. It has turned the process of pharmaceutical transaction and service into a digitalized, standardized and scalable one.
Executives
Chen Xiaohong 2201 Interest of corporation controlled by you
H Capital V Gp, L.p. 2201 Interest of corporation controlled by you
H Capital V Gp, Ltd. 2201 Interest of corporation controlled by you
H Capital V, L.p. 2101 Beneficial owner
Tmf (cayman) Ltd. 2301 Trustee
Tiger Global Private Investment Partners Xi, L.p. 2101 Beneficial owner
Tiger Global Pip Performance Xi, L.p. 2201 Interest of corporation controlled by you
Tiger Global Management, Llc 2102 Investment manager
Shleifer Scott 2201 Interest of corporation controlled by you
Internet Fund Holding V. Ltd. 2201 Interest of corporation controlled by you
Coleman Iii Charles 2201 Interest of corporation controlled by you
Miyt Worldwide Limited 2201 Interest of corporation controlled by you
Miyt Holdings Limited 2101 Beneficial owner
Internet Fund V Pte. Ltd. 2306 Nominee for another person
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. 2101 Beneficial owner

YSB Headlines

No Headlines